[HTML][HTML] Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
X Chen, J Wang, Y Lin, K Yao, Y Xie… - Frontiers in …, 2023 - frontiersin.org
Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular
protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However …
protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However …